PURPOSE: To determine long-term efficacy and safety of riboflavin/ultraviolet A corneal cross-linking (CXL). DESIGN: Prospective cohort study. METHODS: Thirty-six patients (36 eyes) who underwent epithelium-off CXL at a University Hospital (Guy's and St Thomas' National Health Service Foundation Trust) 6-8 years previously were examined. The main outcome measures were refractive error, visual acuity, corneal topographic keratometry, ultrasonic pachymetry, and topography-derived corneal wavefront. RESULTS: At 7 years compared to preoperative values, mean spherical equivalent refractive error (SEQ) increased by +0.78 diopter (D) (P < .005) and mean simulated topographic keratometry (SimK) and mean maximum keratometry (Kmax) reduced by -0.74 D (P < .0001) and -0.91 D (P < .0001), respectively. Uncorrected distance acuity (UCDA) (P < .0005) and corrected distance acuity (CDVA) (P < .0001) had improved and root mean square (RMS) (P < .0005), coma (P < .0005), and secondary astigmatism (P < .005) lessened. At 7 years compared to 1 year, CDVA improved (P < .05); mean SimK (P < .0005) and mean Kmax (P < .005) reduced by -0.45 D and -0.56 D, respectively; and RMS (P < .0005) and coma (P < .0005) decreased. At 7 years compared to 5 years, CDVA improved (P < .05) and trefoil reduced (P < .05). No treated eyes progressed. In 29 initially untreated fellow eyes mean SimK increased by +0.54 D (P < .02), mean Kmax by +0.87 D (P < .05), and refractive astigmatism increased (P < .0005). CONCLUSIONS: Following corneal cross-linking, improvements in topographic and wavefront parameters evident at 1 year were seen to continue to improve at 5 years and were maintained at 7 years. No treated eyes progressed over the 7-year follow-up period.
PURPOSE: To determine long-term efficacy and safety of riboflavin/ultraviolet A corneal cross-linking (CXL). DESIGN: Prospective cohort study. METHODS: Thirty-six patients (36 eyes) who underwent epithelium-off CXL at a University Hospital (Guy's and St Thomas' National Health Service Foundation Trust) 6-8 years previously were examined. The main outcome measures were refractive error, visual acuity, corneal topographic keratometry, ultrasonic pachymetry, and topography-derived corneal wavefront. RESULTS: At 7 years compared to preoperative values, mean spherical equivalent refractive error (SEQ) increased by +0.78 diopter (D) (P < .005) and mean simulated topographic keratometry (SimK) and mean maximum keratometry (Kmax) reduced by -0.74 D (P < .0001) and -0.91 D (P < .0001), respectively. Uncorrected distance acuity (UCDA) (P < .0005) and corrected distance acuity (CDVA) (P < .0001) had improved and root mean square (RMS) (P < .0005), coma (P < .0005), and secondary astigmatism (P < .005) lessened. At 7 years compared to 1 year, CDVA improved (P < .05); mean SimK (P < .0005) and mean Kmax (P < .005) reduced by -0.45 D and -0.56 D, respectively; and RMS (P < .0005) and coma (P < .0005) decreased. At 7 years compared to 5 years, CDVA improved (P < .05) and trefoil reduced (P < .05). No treated eyes progressed. In 29 initially untreated fellow eyes mean SimK increased by +0.54 D (P < .02), mean Kmax by +0.87 D (P < .05), and refractive astigmatism increased (P < .0005). CONCLUSIONS: Following corneal cross-linking, improvements in topographic and wavefront parameters evident at 1 year were seen to continue to improve at 5 years and were maintained at 7 years. No treated eyes progressed over the 7-year follow-up period.
Authors: Jurriaan Brekelmans; Mor M Dickman; Shwetabh Verma; Samuel Arba-Mosquera; Ruth Goldschmidt; Alexandra Goz; Alexander Brandis; Tos T J M Berendschot; Isabelle E Y Saelens; Arie L Marcovich; Avigdor Scherz; Rudy M M A Nuijts Journal: Acta Ophthalmol Date: 2021-09-17 Impact factor: 3.988
Authors: Farideh Doroodgar; Feazollah Niazi; Azad Sanginabadi; Sana Niazi; Alireza Baradaran-Rafii; Cyrus Alinia; Eznollah Azargashb; Mohammad Ghoreishi Journal: BMJ Open Ophthalmol Date: 2017-09-28
Authors: Virgilio Galvis; Alejandro Tello; Néstor I Carreño; Alvaro I Ortiz; Rodrigo Barrera; Carlos Julián Rodriguez; Miguel E Ochoa Journal: Ophthalmol Eye Dis Date: 2016-05-12